Sara M. Tolaney, MD, MPH

Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.

A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.

Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.

Paolo Tarantino, MD, and Sara M. Tolaney, MD, MPH, spoke with CancerNetwork® about highlights from 2022 ASCO in breast cancer research.

This video examines an early trial studying abemaciclib for the treatment of brain metastases in patients with hormone receptor–positive, HER2-negative breast cancer.

This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

This video examines the idea of using clinical features (age, tumor size) to reduce treatment burden in patients with HER2-positive breast cancer.

This video examines chemotherapy options for HER2-positive breast cancer in the adjuvant setting, and what evidence there is for alternatives to an anthracycline backbone.